Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 14/20 | 0.47 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 0.47 |
| ▸ | TNF | P01375 | 3/20 | 0.47 |
| ▸ | IL1B | P01584 | 3/20 | 0.47 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28463995 | 0.80 | CRBN (0.50) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL3965614 | 0.79 | CRBN (0.47) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL31243223 | 0.78 | CRBN (0.47) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL30622070 | 0.75 | CRBN (0.35) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL23985895 | 0.73 | PARP1 (0.38) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL10192652 | 0.73 | CRBN (0.53) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL24440131 | 0.73 | CRBN (0.55) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL10192664 | 0.73 | CRBN (0.53) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL28463988 | 0.73 | CRBN (0.46) | CRBNDDB1BRD4 | |
| SCHEMBL2010576 | 0.71 | CRBN (0.48) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107337667-B | Preparation process of lenalidomide for treating multiple myeloma | 湖南慧泽生物医药科技有限公司 | 2020-10-09 | — | — | CN | claimed |
| CN-107337667-B | Preparation process of lenalidomide for treating multiple myeloma | 湖南慧泽生物医药科技有限公司 | 2020-10-09 | — | — | CN | disclosed |
| CN-107337667-B | Preparation process of lenalidomide for treating multiple myeloma | 湖南慧泽生物医药科技有限公司 | 2020-10-09 | — | — | CN | disclosed |
| US-20110184025-A1 | Methods and Compositions Using Immunomodulatory Compounds for the Treatment and Management of Spirochete and Other Obligate Intracellular Bacterial Diseases | CELGENE CORPORATION | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184025-A1 | Methods and Compositions Using Immunomodulatory Compounds for the Treatment and Management of Spirochete and Other Obligate Intracellular Bacterial Diseases | HSP90B1, MYD88, MSR1 | CRBN 3899/4885DDB1 711/4885IKZF3 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.